A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer

被引：3
|
作者：
Yamashita, Toshinari [1 ]
Shimomura, Akihiko [2 ]
Takano, Toshimi [3 ]
Sagara, Yasuaki [4 ]
Watanabe, Junichiro [5 ]
Tokunaga, Eriko [6 ]
Kikumori, Kunika [7 ]
Kamiyama, Emi [7 ]
Kamio, Takahiro [7 ]
Nakamura, Ryo [7 ]
Shinkai, Tetsu [8 ]
Takahashi, Shunji [9 ]
机构：
[1] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Toranomon Gen Hosp, Tokyo, Japan
[4] Hakuaikai Sagara Hosp, Social Med Corp, Kagoshima, Japan
[5] Shizuoka Canc Ctr, Shizuoka, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[7] Daiichi Sankyo Co Ltd, Tokyo, Japan
[8] Shonan Tobu Sougou Hosp, Kamakura, Kanagawa, Japan
[9] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P1-18-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-12
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
    Chang, Dwan-Ying
    Lin, Chia-Chi
    Chen, Tom Wei-Wu
    Lin, Ching-Hung
    Lee, Jih-Hsiang
    Chao, Ta-Chung
    Liu, Chun-Yu
    Achiwa, Issei
    Kamiyama, Emi
    Okuda, Yasuyuki
    Lee, Caleb
    Chao, Yee
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [2] A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS 8201a) in subjects with HER2-expressing gastric cancer.
    Shitara, Kohei
    Bang, Yung-Jue
    Chung, Hyun Cheol
    Yabusaki, Hiroshi
    Iwasa, Satoru
    Sakai, Daisuke
    Muro, Kei
    Sugimoto, Naotoshi
    Yasui, Hisateru
    Gamoh, Makio
    Murakawa, Yasuko
    Negoro, Yuji
    Nishina, Tomohiro
    Hosaka, Hisashi
    Omuro, Yasushi
    Kawaguchi, Yoshinori
    Sugihara, Masahiro
    Saito, Kaku
    Dalal, Rita
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [3] A randomized, phase II, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer
    Shitara, K.
    Bang, Y-J.
    Sakai, D.
    Yasui, H.
    Kawaguchi, Y.
    Sugihara, M.
    Saito, K.
    Dalal, R.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 65 - 65
  • [4] [Fam-] Trastuzumab Deruxtecan (T-DXd; DS-8201a) in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: A Phase 2, Multicenter, Open-Label Study (DESTINY-Breast01)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 7 - 9
  • [5] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)
    Krop, Ian E.
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara
    Cortes, Javier
    Lee, Caleb
    Chen, Shuquan
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Modi, Shanu
    CANCER RESEARCH, 2020, 80 (04)
  • [6] A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Sakai, Daisuke
    Yasui, Hisateru
    Kawaguchi, Yoshinori
    Sugihara, Masahiro
    Saito, Kaku
    Dalal, Rita
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Fuchs, Charles S.
    Shahidi, Javad
    Mathew, Lijoy
    Qin, Amy
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 45 - 45
  • [9] A phase 3, multicenter, randomized, open-label trial of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Modi, Shanu
    Ohtani, Shoichiro
    Lee, Caleb
    Wang, Yibin
    Saxena, Kapil
    Cameron, David A.
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study
    Hamilton, Erika
    Shapiro, Charles L.
    Petrylak, Daniel
    Boni, Valentina
    Martin, Miguel
    Del Conte, Gianluca
    Cortes, Javier
    Agarwal, Laila
    Arkenau, Hendrik-Tobias
    Tan, Antoinette R.
    Debruyne, Philip
    Minchom, Anna
    Rutten, Annemie
    Valdes-Albini, Frances
    Yu, Evan Y.
    Augustine, Bincy
    D'Amelio, Anthony, Jr.
    Barrios, Daniel
    Hurvitz, Sara A.
    CANCER RESEARCH, 2021, 81 (04)
12345